key: cord-0964893-1dldp2st
authors: Vellas, Camille; Tremeaux, Pauline; Del Bello, Arnaud; Latour, Justine; Jeanne, Nicolas; Ranger, Noémie; Danet, Chloé; Martin-Blondel, Guillaume; Delobel, Pierre; Kamar, Nassim; Izopet, Jacques
title: Resistance mutations in SARS-CoV-2 omicron variant in patients treated with Sotrovimab
date: 2022-05-17
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.05.002
sha: cc002ab68fa1364cee362cd23d1ba397be0e4f0c
doc_id: 964893
cord_uid: 1dldp2st

nan

To the Editor, the majority of RBD-targeting monoclonal antibodies (mAb) [1] . Sotrovimab, a pan-32 sarbecovirus neutralizing mAb recently authorized, seems to remain efficient to neutralize 33 omicron variant [1, 2] . However, as it targets a single epitope, the risk of developing 34 resistance mutations is not negligible. We determined the evolution of the virus load, the Figure S1 ). The 

Omicron escapes the 127 majority of existing SARS-CoV-2 neutralizing antibodies

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With 131 Mild to Moderate COVID-19: A Randomized Clinical Trial

Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 135 nasopharyngeal load and quasispecies

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent 139 in vitro and in vivo activity against

Antibody evasion 142 properties of SARS-CoV-2 Omicron sublineages

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

Time after Sotrovimab infusion when the mutation was first detected c Rebound of the viral load after mutation emergence, c slight decline means viral load decline < 1 log10 copies/ml, decline means viral load decline > 1 log10 copies/ml,